CAMKK1 as a novel regenerative therapeutic
Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.
1. A method of preventing fibrosis or increasing vascular density in an organ or tissue of a patient, the method comprising administering to the patient:
(a) cells comprising:
a vector comprising a nucleic acid encoding human calcium/calmodulin-dependent protein kinase kinase 1 (CAMKK1) selected from the group of: the protein of SEQ ID NO: 4, the T108A mutant CAMKK1, the S459A mutant CAMKK1, or the T108A/S459A mutant CAMKK1, wherein T108 corresponds to position 108 of SEQ ID NO: 2 and S459 corresponds to position 458 of SEQ ID NO: 2, to said organ or tissue, and optionally wherein the vector is a plasmid or a viral vector; or
(b) conditioned media from a culture of the cells of (a) that have been modified to have an increase of the level of human CAMKK1 protein to said organ or tissue, thereby preventing fibrosis or increasing vascular density in the organ or tissue of the patient.
2. The method of claim 1 , wherein said organ or tissue is heart, myocardium, liver, kidney, brain, spine, lungs, small intestine, large intestine, arteries, joints, cartilage, skin, or any combination thereof.
3. The method of claim 1 , wherein the cells have been modified with the vector comprising the nucleic acid encoding human CAMKK1 to express an elevated level of human CAMKK1.
4. The method of claim 1 , wherein the cells or conditioned media are administered systemically, directly into said organ or tissue, or about the periphery of said organ or tissue, wherein said organ or tissue is inflamed or damaged.
5. The method of claim 1 , wherein the cells are mesenchymal stem cells.
6. The method of claim 1 , further comprising administering one or more additional regenerative therapies.
7. The method of claim 6 , wherein the one or more regenerative therapies comprise administering mesenchymal stem cells derived from bone marrow, adipose tissue, placental tissue, umbilical cord, Wharton's Jelly, menstrual blood, stem cells, M2 macrophages, monocytes, or any combination thereof.
8. The method of claim 7 , wherein the stem cells are neural progenitor cells, endothelial progenitor cells, organ specific endogenous stem cells, or any combination thereof.
9. The method of claim 8 , wherein the organ specific endogenous stem cells are cardiac ckit+cells.
10. The method of claim 1 , wherein the organ or tissue is heart or myocardium.
11. The method of claim 10 , wherein the heart or myocardium is associated with a condition of heart failure or stroke, wherein the heart failure is with or without ejection fraction.
12. A method of preventing fibrosis or increasing vascular density in an organ or tissue of a patient by modulating a secretome expression of a cell in said organ or tissue by human CAMKK1, the method comprising:
administering a vector comprising a nucleic acid encoding human calcium/calmodulin-dependent protein kinase kinase 1 (CAMKK1) selected from the group of: the protein of SEQ ID NO: 4, the T108A mutant CAMKKI, the S459A mutant CAMKK, or the T108A/S459A mutant CAMKKI, wherein T108 corresponds to position 108 of SEQ ID NO: 2 and S459 corresponds to position 458 of SEQ ID NO: 2, to a cell of said organ or tissue thereby inducing an increased level of human CAMKK1 in the cell, and optionally wherein the vector is a plasmid or a viral vector,
thereby modulating a secretome expression of the cell by the human CAMKK1 to prevent fibrosis or increase vascular density in the organ or tissue in the patient.
13. The method of claim 12 , wherein said organ or tissue is heart, myocardium, liver, kidney, brain, spine, lungs, small intestine, large intestine, arteries, joints, cartilage, skin, or any combination thereof.
14. The method of claim 12 , wherein the organ or tissue is heart or myocardium.